RxDoctor Payments Data

Amanda Barry

Acute Care · Jackson, MSNPI 1851575880

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.

$3,669in general payments, 2019–2025

Across 148 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$704
  • Abiomed$632
  • Novartis$612
  • Boston Scientific$359
  • AstraZeneca$306
  • Merck$158
  • plus $898 from 21 others

What the payments were for

  • Food & beverage$3,61999%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,669 in reported general payments places this provider in the 85th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi

Medicare billing

Part B allowed, 2024
$15,619
Medicare patients
192
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan17$19,756
JardianceEmpagliflozin28$16,833
EliquisApixaban18$13,263
Metoprolol Succinate44$369
Lisinopril12$285
Carvedilol49$256
Amlodipine Besylate33$212
ClopidogrelClopidogrel Bisulfate25$192
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide13$130
Losartan Potassium17$124
Spironolactone21$112
Isosorbide Mononitrate ErIsosorbide Mononitrate15$95
Atorvastatin Calcium17$92
Rosuvastatin Calcium15$85
Hydralazine Hcl11$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$612$19,75617 claims
Boehringer IngelheimJardiance$704$16,83328 claims
PfizerEliquis$41$13,26318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 acute care providers in Mississippi.

Other acute care in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →